Mar 14th 2013 - Edison Investment Research today published a report on wilex entitled "Rencarex Redux?". In summary, the report says:
Wilex reported €13.9m revenues in 2012 from the Rencarex deal with Prometheus as revenue recognition accelerated after ARISER trial did not meet its endpoint; €10.1m will be recognised in FY13. The main value in 2013 lies in partnering Mesupron. This is essential to progress the project. Redectane for kidney cancer imaging should enter a second US Phase III in Q2. The Heidelberg Pharma subsidiary offers novel chemistry links between antibodies and therapeutic payloads and is expected to grow its FY12 revenues of €1.9m in FY13. Wilex is funded into 2014 before any deal payments. Year-end cash was €23.7m; cash use in FY13 may be €18m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »